Eyeluminaries

Eyeluminaries

By John Hovanesian, MD, FACS and Jim MazzoMedicineHealth & Fitness
Download on the App Store

Eyeluminaries episodes

  • The Latest News and Notes, plus Conversation with Stephen McLeod, MD

    Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Stephen McLeod, MD, about his new position and the future of the American Academy of Ophthalmology.

    · Welcome to the Eyeluminaries podcast :01

    · Review of episode 15, live from Eyecelerator :37

    · Preview of episode 17, live at Octane OTS 1:07s

    · Théa to acquire seven branded ophthalmic products from Akorn 2:17

    · FDA approves Miebo to treat signs, symptoms of dry eye disease 5:11

    · OCS-01 eye drops meet primary, secondary endpoints in diabetic macular edema phase 3 trial 8:56

    · 'One of my greatest honors': Jim Mazzo awarded Ellis Island Medal of Honor 10:38

    · Introduction Stephen McLeod, MD 12:14

    · What's been your biggest challenge transitioning from clinical practice to your current position? 14:16

    · Where is the AAO going now? 17:50

    · Prior authorizations are the bane of operational existence. What is AAOs role in reforming this system? 22:59

    · The future of meetings 30:27

    · Preview of episode 17 35:44

    · Feedback, questions and guest suggestions at [email protected] 36:47

    · Thanks for listening 54:02

    John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.

    Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.

    Stephen McLeod, MD, is the CEO of the American Academy of Ophthalmology.

    We'd love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on Twitter @DrHovanesian.

    Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. McLeod is the CEO of the American Academy of Ophthalmology.

    38 min
  • Live from Eyecelerator 2023

    Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, are live at the Eyecelerator 2023 with five special guests to discuss the future and developments in eye care.

    · Welcome to the Eyeluminaries podcast :00

    · Preview of episode 15 :32

    · Review of episode 14, STAAR Surgical :40

    · Nick Curtis, CEO of Lensar 1:41

    · Lensar is a unique company with loyal customers. How have you achieved that? 3:21

    · What are the positives and challenges to not having a large organization as support? 4:09

    · Where do you see the company and its products evolving over the next 5 years? 8:01

    · Do you think the company is going to grow because you are taking share? Or because you are taking share and the market is going to grow? 10:06

    · What is the accelerator for market growth? 10:19

    · Who's your favorite Chicago team? 12:03

    · Juliet Bakker, managing director and founder of Longitude Capital 13:11

    · What makes ophthalmology an appealing specialty to you from an investment and a personal perspective? 14:30

    · Give a sense of how you see Eyecelerator as an investor. 18:32

    · What did you learn from failed investments? 21:39

    · What are the signs of success that you look for? 23:03

    · Ramin Valian, vice president Eye Care Allergan/AbbVie 24:31

    · What is happening in ophthalmology at AbbVie? 25:21

    · What were the key learnings after launching Vuity? 27:52

    · Does ophthalmology have the same momentum as aesthetics? 30:12

    · Susan Siw Daniels, PhD, chief scientific officer at Avellino Labs 34:11

    · Why is your background perfect for Avellino? 35:06

    · What things did you see transform in other specialties that you see potentially happening in ophthalmology? 38:02

    · What data are you looking for to expand predictive testing and treatments in eye care in the future? 39:07

    · How do you get ophthalmologists more involved in genetic testing? 40:30

    · Julie Schallhorn, MD, MS 43:00

    · What's new at the Eyecelerator? 44:42

    · What are the signs of success in a startup company? 47:44

    · What is your advice for people who want to balance their time with a medical career and personal life? 49:45

    · Preview of episode 16 53:28

    · Feedback, questions and guest suggestions at [email protected] 53:56

    · Thanks for listening 54:02

    Juliet Bakker is a managing director and founder of Longitude Capital.

    Nick Curtis is chief executive officer and member of the board of directors at Lensar.

    Susan Siw Daniels, PhD, is the chief scientific officer at Avellino.

    John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.

    Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.

    Julie Schallhorn, MD, MS, is an assistant professor of ophthalmology at UCSF.

    Ramin Valian is the vice president of Eye Care Allergan/AbbVie.

    We'd love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on Twitter @DrHovanesian.

    Disclosures: Bakker serves on the boards of Ceribell, Engogenex, Nalu Medical and RxSight. Curtis is a member of the board of directors for Lensar. Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Schallhorn sits on the Ophthalmic Technology Assessment Committee for Refractive Surgery for the American Academy of Ophthalmolgy and the Young Eye Surgeons Committee for the American Society of Cataract and Refractive Surgeons.

    55 min
  • Conversation with Tom Frinzi, Warren Foust and Magda Michna about STAAR Surgical

    Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the new leadership at STAAR Surgical with Tom Frinzi, president and CEO; Warren Foust, COO; and Magda Michna, PhD. • Welcome to the Eyeluminaries podcast :00 • Review of episode 13 with Gil Kliman, MD :23 • Review of episode 12, the Annual Drug Name Awards :52 • Preview of episode 14 1:20 • Tom Frinzi, president and CEO; Warren Foust, COO; and Magda Michna, PhD, introduction 1:28 • Tom: What were the qualities and factors that made you choose Foust and Michna to join the STAAR Surgical team? 3:42 • Magda: Why STAAR Surgical? 6:07 • Magda: What can you do to help repair the relationship between STAAR Surgical and the FDA? And what do you hope to change at STAAR? 8:07 • Warren and Magda: What's the 100-day plan? 9:47 • Tom: How does STAAR Surgical plan to make the ICL exciting for doctors and patients in the US? 13:17 • Warren: How do you get physicians excited about the ICL? 16:26 • Tom and Warren: How do you compete with other companies that have an advantage when it comes to selling STAAR's technology? 18:20 • What kind of impact would you like to have on STAAR Surgical 3 to 5 years from now? 23:14 • STAAR Surgical and the Jonas Brothers 28:25 • Wrap up and thank you, Tom, Warren and Magda 29:51 • Preview of episode 15 30:04 • Feedback, questions and guest suggestions at [email protected] 31:00 • Thanks for listening 31:36 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Warren Foust is the chief operating officer at STAAR Surgical. Thomas Frinzi is the president and chief executive officer at STAAR Surgical. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Magda Michna, PhD, is the chief clinical, regulatory and medical affairs officer at STAAR Surgical. We'd love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Foust is the chief operating officer at STAAR Surgical. Frinzi is the president and chief executive officer at STAAR Surgical.

    32 min
  • Conversation with Gil Kliman, MD, about Silicon Valley Bank

    Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the Silicon Valley Bank collapse and its impact on investing and innovation in the field of ophthalmology with Gilbert H. Kliman, MD.

    · Welcome to the Eyeluminaries podcast :01

    · Review of episode 12 with Richard L. Lindstrom, MD :30

    · Preview of episode 13 1:35

    · Gil Kliman, MD, introduction 2:36

    · History of Silicon Valley Bank 4:25

    · Silicon Valley Bank's collapse 6:08

    · Guest welcome 8:07

    · Was the collapse a surprise? 8:22

    · Kliman on major themes of this event being how fast it happened and how unprecedented it was for companies 9:34

    · How many ophthalmic companies have been affected, and what are the next steps for these companies? 10:16

    · Kliman on the turning point when the FDIC stepped in on Sunday 11:50

    · Have you had companies report that they have accessed their funds at Silicon Valley Bank? 12:27

    · Kliman on his experience with Silicon Valley Bank 12:45

    · What should companies do going forward, and what are you advising companies? 14:17

    · Kliman on figuring out a new strategy and the unique issue of 90% of depositors being above the $250,000 FDIC threshold 16:13

    · What is the survival rate for small banks now? 17:31

    · What do you think the flavor of the room will be at Eyecelerator@ASCRS? 19:20

    · Kliman's advice for companies to focus on burn rates 20:35

    · The physician's perspective for supporting innovation and small business 21:54

    · How strategics can continue to partner with startups using their venture arm 24:04

    · Information on the Eyecelerator meeting 25:46

    · Wrap up and thank you, Gil 26:16

    · Feedback, questions and guest suggestions at [email protected] 26:45

    · Thanks for listening, and preview of episode 14 27:11 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.

    Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.

    Gil Kliman, MD, is managing partner at InterWest Partners and is co-founder and program director of Eyecelerator.

    We'd love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on Twitter @DrHovanesian.

    Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Kliman is managing partner at InterWest Partners.

    28 min
  • The Latest News and Notes, plus Conversation with Richard L. Lindstrom, MD

    Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Richard L. Lindstrom, MD, about the latest news and trends, as well as his career and his advice for residents and entrepreneurs in the field of ophthalmology.

    • Welcome to the Eyeluminaries podcast :00
    • OTF Meeting 01:41
    • Gezundheit award – Iheezo (chloroprocaine hydrochloride ophthalmic gel) 4:04
    • Name stolen from a birthday party magician award – Vabysmo (faricimab-svoa) 4:42
    • The incomplete sentence award – Iyuzeh (latanoprost ophthalmic solution) 5:21
    • Big improvement on the generic name award – Zimura (avacincaptad pegol) 6:24
    • Best of the year award – Pegcetacoplan 6:49
    • Near miss award – Beovu (brolucizumab) 8:08
    • Awful award – Byooviz (ranibizumab-nuna) 8:45
    • Guest welcome 9:40
    • Richard L. Lindstrom, MD, introduction 10:31
    • FDA grants fast track designation for retinitis pigmentosa treatment 10:36
    • EyeArt AI system approved in EU for detecting AMD, glaucomatous optic nerve damage 13:14
    • Amazon launches discount prescription drug service 17:46
    • Interview with Lindstrom 21:42
    • What is the biggest innovation in ophthalmology in your career? 22:40
    • What is coming in the next 10 years? 25:24
    • What is out there that will get in the way of innovation? 26:54
    • What advice would you give to residents? 28:35
    • What advice would you give to entrepreneurs? 30:16
    • What story can you share about one historical figure in ophthalmology? 31:59
    • Wrap up and a preview of episode 13, guest David Endicot, Alcon CEO 35:14
    • Feedback, questions and guest suggestions at [email protected] 36:29
    • Thanks for listening 36:53

    John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.

    Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO.

    Richard L. Lindstrom, MD, is the founder and an Attending Surgeon at Minnesota Eye Consultants and an Adjunct Professor Emeritus at the University of Minnesota, Department of Ophthalmology. He is a board-certified Ophthalmologist and an internationally recognized leader in corneal, cataract, refractive and laser surgery.

    We'd love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on Twitter @DrHovanesian.

    Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Lindstrom reports consulting with AcuFocus, Alcon, Allergan, Bausch + Lomb, Combangio, CorneaGen, Equinox, Eyevance/Santen, Flying L Partners, Harrow Health, J&J Vision, Lensar, Lentechs, MDbackline, Novartis, Orasis, Schroeder Vision Life Sciences, Sun, Surface, Versant Ventures, Visionary Ventures and Zeiss; holds stocks with Acquea, AcuFocus, Combangio, CorneaGen, Equinox, Flying L Investments, ForSight, Harrow Health, Lensar, Lentechs, MDbackline, Ocular Therapeutix, Orasis, Sight4All, Surface, TearClear, TearLab, TherOptix, Unifeye Vision Partners and Visionary Ventures; board chairman of Surface; sits on the board of Acquea, AcuFocus, Combangio, CorneaGen, Equinox, ForSight, Harrow Health, Lensar, Lentechs, MDbackline, Ocular Therapeutix, Sight4All, TearLab, TherOptix and Unifeye Vision Partners; board observer of TearClear; receives compensation from Ocular Therapeutix; member of the investment committee of Flying L Investments and Visionary Ventures; and a medical advisory board member of Acquea, Foresight, Harrow Health, Ocular Therapeutix, Sight4All, TearClear and TearLab.

    38 min
  • The Latest News and Notes, live from Hawaiian Eye

    Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest news stories, live from Hawaiian Eye.

    • Welcome to the Eyeluminaries podcast :01
    • Review of episode 10, the Allergan alumni guests 1:30
    • Bausch + Lomb announces acquisition of AcuFocus 3:39
    • Mazzo attributes success to people and the magic of ophthalmology 5:40
    • Keranova's PhotoEmulsification technique shows promising results 9:25
    • Centricity CEO discusses latest cataract surgery products 11:04
    • Orasis submits new drug application for presbyopia drop 12:30
    • Aldeyra submits NDA for primary vitreoretinal lymphoma treatment 15:27
    • Iveric Bio submits final part of Zimura new drug application for rolling review 17:30
    • Tom Frinzi to become CEO of STAAR Surgical 22:37
    • Wrap up and a preview of episode 12 25:38
    • Feedback, questions and guest suggestions at [email protected] 27:39
    • Thanks for listening 28:00

    John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.

    Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO.

    We'd love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on Twitter @DrHovanesian.

    Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.

    29 min
  • The Latest News and Notes, plus Conversation with Allergan alumni

    Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, sit down with Gavin Herbert, Tom Burns, Andy Corley and Tom Mitro to discuss their days at Allergan and what they have learned from their experiences.

    • Welcome to the Eyeluminaries podcast :37
    • News and notes with John and Jim 1:01
    • Viatris to acquire Oyster Point, Famy Life Sciences 1:06
    • Ocuphire enters global license agreement with Famy for Nyxol development 4:20
    • Eyenuk secures $26 million in Series A funding 6:24
    • Encapsulated cell therapy shows positive results for macular telangiectasia 8:31
    • Introduction of the Allergan alumni 10:35
    • The interview 12:10
    • Gavin Herbert – what is the secret to great leadership? 12:18
    • Tom Burns – what have you learned from Allergan that has led to your success? 17:48
    • Andy Corley 20:38
    • Tom Mitro 24:50
    • Jim Mazzo 29:41
    • Herbert – principles 30:29
    • Corley – producing jobs 32:01
    • Herbert – alumni 32:50
    • Wrap up and a preview of episode 10 33:38
    • Feedback, questions and guest suggestions at [email protected] 34:06
    • Thanks for listening 34:14

    John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.

    Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO.

    Gavin Herbert is a board member of the Doheny Eye Institute and the Nixon Foundation, as well as a life trustee of the University of Southern California. He was the co-founder and chief executive officer of Allergan Inc.

    Tom Mitro is the past president and chief operating officer at Aerie Pharmaceuticals.

    Tom Burns serves as the chief executive officer and the chairman of the board for Glaukos.

    Andy Corley is the founder of Yelroc Consulting, Inc.

    We'd love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on Twitter @DrHovanesian.

    Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Herbert reports being a board member of the Doheny Eye Institute and the Nixon Foundation, as well as a life trustee of the University of Southern California. He was the co-founder and chief executive officer of Allergan Inc. Mitro is the past president and chief operating officer at Aerie Pharmaceuticals. Burns serves as the chief executive officer and the chairman of the board for Glaukos. Corley is the founder of Yelroc Consulting, Inc.

    35 min
  • The Latest News and Notes, plus Conversation with the Schallhorn family

    Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest ophthalmic industry news and interview Steve Schallhorn, MD, Julie Schallhorn, MD, Craig S. Schallhorn, MD, Erin Schallhorn and Eileen Schallhorn.

    • Welcome to the Eyeluminaries podcast :01
    • A preview of the guests :32
    • A review of the previous episode 1:32
    • News and notes with John and Jim 1:52
    • Iantrek raises $23 million for MIGS device trials 1:57
    • Q&A: Data show safety of in-office ophthalmic surgery 4:34
    • TearLab rebrands as Trukera Medical 7:04
    • Coherus to launch ranibizumab biosimilar in October 10:46
    • Introduction of the Schallhorn family 14:38
    • The interview 16:29
    • Steve Schallhorn, MD – naval aviator and Top Gun 17:04
    • Eileen Schallhorn – fostering the children to become the best they can be 20:05
    • Steve and Eileen – three successful children in the field of ophthalmology 21:28
    • Julie Schallhorn, MD – growing up and becoming an ophthalmologist 22:57
    • Craig Schallhorn, MD – specializing in retina 24:52
    • Erin Schallhorn (Powers) – choosing the industry of ophthalmology 27:36
    • Steve – never underestimate Erin 31:06
    • Julie and Craig – following in their father's footsteps 32:02
    • Julie, Craig and Erin – What do you want to say to mom and dad? 36:32
    • Eileen – love makes it work 38:32
    • Wrap up and a preview of episode ten 39:04
    • Feedback, questions and guest suggestions at [email protected] 39:38
    • Thanks for listening 40:32

    Steve Schallhorn, MD, is a board certified, licensed ophthalmologist in private practice in San Diego, CA. He is a clinical professor of ophthalmology at the University of California, San Francisco; chief medical officer for Carl Zeiss Meditec and chairman of the Optical Express Medical Advisor Board.

    Julie Schallhorn, MD, is associate director of the University of California, San Diego, residency program in ophthalmology, organizing classroom and research curricula for residents.

    Craig Steven Schallhorn, MD, is an ophthalmologist in San Francisco, CA.

    Erin Schallhorn Powers is the vice president of Global Marketing & Product Strategy at BVI Medical.

    John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.

    Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO.

    We'd love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on Twitter @DrHovanesian. You can find Dr. Ianchulev on LinkedIn: Sean Ianchulev, MD, MPH.

    Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.

    41 min
  • The Latest News and Notes, plus Conversation with Sean Ianchulev, MD, MPH

    Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest ophthalmic industry news and interview Sean Ianchulev, MD, MPH.

    • Welcome to the Eyeluminaries podcast :01
    • A review of the previous episode :23
    • News and notes with John and Jim 1:31
    • Alcon to acquire Aerie Pharmaceuticals 1:40
    • Glaukos, iVeena enter licensing agreement for keratoconus treatment 5:20
    • Lions Eye Institute to acquire SightLife 8:37
    • Novaliq submits NDA for CyclASol for treatment of dry eye disease 11:37
    • AbbVie, iSTAR enter alliance to support MINIject MIGS device 13:30
    • Introduction of Sean Ianchulev 16:30
    • The interview 18:37
    • Impact on Google Glass 21:32
    • What innovations are you proud of and what projects are you excited about? 26:20
    • What advice do you have for new entrepreneurs? 33:04
    • How do you balance your work life and your home life? 36:24
    • Legends in the field of ophthalmology 38:07
    • Give feedback at [email protected] 39:39
    • A preview of the next episode of Eyeluminaries 39:54
    • Thanks for listening 40:26

    Sean Ianchulev, MD, MPH, is a Harvard-trained physician-scientist, a professor of ophthalmology and the head of innovation and technology at New York Eye and Ear Infirmary founder and chairman of Iantrek Inc and Eyenovia and serves as a board member for the American Society of Cataract and Refractive Surgery Foundation and AEYE Health.

    John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.

    Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO.

    We'd love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on Twitter @DrHovanesian. You can find Dr. Ianchulev on LinkedIn: Sean Ianchulev, MD, MPH.

    Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.

    41 min
  • The Latest News and Notes, plus Conversation with David F. Chang, MD

    Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest ophthalmic industry news and interview David F. Chang, MD.

    • Welcome to the Eyeluminaries podcast :10
    • A review of the previous episode :30
    • News and notes with John and Jim 1:15
    • AMA president outlines 5 actions for policymakers to take to support physicians 1:20
    • Aetna drops prior authorization requirement for cataract surgery 4:10
    • Yutiq approved in China 6:21
    • Lensar received FDA 510(k) clearance for its next-generation Ally adaptive cataract treatment system 8:55
    • Introduction of David F. Chang, MD 10:30
    • The interview 11:48
    • How did EyeSustain develop and how can people become involved? 13:54
    • What are you doing differently already in your surgery center or office to reduce waste? 18:27
    • Tell us your thoughts on same-day bilateral cataract surgery and intracameral antibiotics 21:02
    • What technological advancements do you see coming here from outside the U.S? 25:18
    • An anecdote on parenting, baseball and myopia 31:16
    • A preview of the next episode of Eyeluminaries 33:08

    David F. Chang, MD, is a world-renowned cataract surgeon and innovator in the field. He is clinical professor of ophthalmology at the University of California, San Francisco, and is in private practice in Los Altos, Calif.

    John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.

    Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO.

    We'd love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on Twitter @DrHovanesian.

    Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.

    35 min

About Eyeluminaries

From the publisher's feed

A podcast hosted by John A. Hovanesian, MD, and Jim Mazzo who explore the latest news and trends with newsmakers and visionaries in eye care.

More shows like Eyeluminaries

White Coat Investor Podcast by Dr. Jim Dahle of the White Coat Investor

White Coat Investor Podcast

2,445 Listeners

Healio Rheuminations by Adam J. Brown, MD

Healio Rheuminations

121 Listeners

Eye Care Out Loud by Darrell White

Eye Care Out Loud

9 Listeners

Gut Talk by Sameer K. Berry, MD, and William D. Chey, MD

Gut Talk

31 Listeners

Unmasking COVID-19 by Healio

Unmasking COVID-19

30 Listeners

Meeting Mic by Healio

Meeting Mic

5 Listeners

Oncology Overdrive by Shikha Jain, MD

Oncology Overdrive

15 Listeners

Eye Care Insider by Joshua Mali, MD

Eye Care Insider

5 Listeners

Vital Capacity by Abhishek Bhardwaj, MD

Vital Capacity

13 Listeners

Experts InSight by American Academy of Ophthalmology

Experts InSight

50 Listeners

Mend the Gap: Equity in Medicine by Healio

Mend the Gap: Equity in Medicine

6 Listeners